Compounds > lutetium
Page last updated: 2024-08-22

lutetium and Melanoma

lutetium has been researched along with Melanoma in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's4 (57.14)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Begin-Colin, S; Bordeianu, C; Boutry, S; Chezal, JM; Cinotti, E; Felder-Flesch, D; Jouberton, E; Labeille, B; Laurent, S; Meyer, F; Miot-Noirault, E; Muller, RN; Parat, A; Perrot, JL; Piant, S; Walter, A; Zbaraszczuk-Affolter, C1
Chakraborty, S; Pillai, MR; Sarma, HD; Vimalnath, KV1
Anderson, CJ; Beaino, W; Nedrow, JR1
Alonso, O; Cabral, P; Calzada, V; Camacho, X; Chammas, R; Fernandez, M; Gambini, JP; Riva, E1
Fisher, DR; Miao, Y; Quinn, TP1
Bakker, WH; de Herder, WW; Feelders, RA; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; van Essen, M; Wolbers, JG1
Miao, Y; Quinn, TP; Shelton, T1

Other Studies

7 other study(ies) available for lutetium and Melanoma

ArticleYear
Evaluation of the Active Targeting of Melanin Granules after Intravenous Injection of Dendronized Nanoparticles.
    Molecular pharmaceutics, 2018, 02-05, Volume: 15, Issue:2

    Topics: Animals; Biopsy; Cell Line, Tumor; Humans; Injections, Intravenous; Lutetium; Magnetic Resonance Imaging; Male; Melanins; Melanoma; Mice; Microscopy, Confocal; Nanoparticles; Polymers; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Skin; Skin Neoplasms; Tissue Distribution

2018
Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
    Nuclear medicine and biology, 2013, Volume: 40, Issue:7

    Topics: Animals; Dimerization; Drug Stability; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Melanoma; Mice; Octanols; Peptides, Cyclic; Radiation Dosage; Radioactive Tracers; Radiochemistry; Radioisotopes; Water

2013
Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.
    Molecular pharmaceutics, 2015, Jun-01, Volume: 12, Issue:6

    Topics: Animals; Cell Line, Tumor; Gallium Radioisotopes; Humans; Integrin alpha4beta1; Lutetium; Male; Melanoma; Melanoma, Cutaneous Malignant; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Positron-Emission Tomography; Radioisotopes; Skin Neoplasms

2015
177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma.
    Current radiopharmaceuticals, 2017, Volume: 10, Issue:1

    Topics: Animals; Bevacizumab; Lutetium; Male; Melanoma; Mice; Mice, Inbred C57BL; Radioimmunotherapy; Radioisotopes; Radionuclide Imaging; Succinimides; Tissue Distribution

2017
Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues.
    Nuclear medicine and biology, 2006, Volume: 33, Issue:6

    Topics: alpha-MSH; Animals; Kidney; Lutetium; Melanoma; Mice; Mice, Inbred C57BL; Radioisotopes; Radiopharmaceuticals; Tissue Distribution; Yttrium Radioisotopes

2006
Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006, Volume: 47, Issue:10

    Topics: Adult; Aged; Carcinoma, Small Cell; Eye Neoplasms; Female; Humans; Lung Neoplasms; Lutetium; Male; Melanoma; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Metastasis; Octreotide; Paraganglioma; Radioisotopes; Radiopharmaceuticals

2006
Therapeutic efficacy of a 177Lu-labeled DOTA conjugated alpha-melanocyte-stimulating hormone peptide in a murine melanoma-bearing mouse model.
    Cancer biotherapy & radiopharmaceuticals, 2007, Volume: 22, Issue:3

    Topics: alpha-MSH; Animals; Arginine; Chelating Agents; Disease Models, Animal; Heterocyclic Compounds, 1-Ring; Kidney; Lutetium; Melanoma; Mice; Radiography; Radioisotopes; Survival Analysis

2007